Psoriasis and Vitamin D3
- 1 February 1989
- journal article
- review article
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 125 (2) , 231-234
- https://doi.org/10.1001/archderm.1989.01670140083015
Abstract
• Psoriasis is associated with abnormally exaggerated epidermal cellular turnover. Recent studies showed that calcitriol (1,25-dihydroxyvitamin D3) a calcitrophic hormone, regulates terminal differentiation of basal cells of epidermal keratinocytes. We administered active forms of vitamin D3in both oral and topical ways in an opendesign study to patients with psoriasis vulgaris. Significant improvement was observed at the end of the study periods in these patients, especially in those treated with topical application of calcitriol. We also found a significant negative correlation between the severity of psoriasis and the basal serum level of 1α,25-dihydroxyvitamin D but not with those of other calcium-related parameters in psoriatic patients. These data suggest that exogenous active forms of vitamin D3are effective for treatment of psoriasis and that the endogenous 1,25-dihydroxyvitamin D level also may be involved in the development of this skin disease. (Arch Dermatol1989;125:231-234)Keywords
This publication has 2 references indexed in Scilit:
- [55] Competitive protein binding assay for plasma 25-hydroxycholecalciferolPublished by Elsevier ,1980
- Severe Psoriasis – Oral Therapy with a New RetinoidDermatology, 1978